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S8 Journal of Thoracic Oncology Vol. 11 No. 2SWhile we have shown that these urinary metabolites
are risk biomarkers for lung cancer in these studies, they
are not fully predictive. This is because these biomarkers
are mainly measuring exposure but do not take into ac-
count the critical metabolic activation step leading to the
formation of DNA adducts which cause the multiple
mutations observed in lung cancer. Quantitation of DNA
adducts is challenging because of their low levels, typi-
cally less than 1 adduct per 107 normal bases, and the
small amounts of DNA available for studies in living
humans. To address this question, we are developing high
resolution mass spectrometric methods for quantifying
oral cell DNA adducts as a surrogate for DNA adduct
formation in the lung. In one recent study, we found
remarkably high levels of DNA adducts of tobacco-
speciﬁc compounds in in the oral mucosa cells of smokers
compared to non-smokers. We are also able to quantify
formaldehyde-DNA adducts in oral mucosa cells. As mass
spectrometric methods for analysis of carcinogen-DNA
adducts become increasingly more sensitive and speciﬁc,
it appears likely that quantitation of a panel of tobacco
carcinogen DNA adducts in smokers, leading to identiﬁ-
cation of susceptible individuals, may be feasible.
Targeting PD1 and PDL1 in lung cancer
treatment: Where are we now?Roy S. Herbst Yale Cancer Center,
New Haven, CTThe therapy for advanced non-small cell lung cancer has
improved dramatically in recent years. We have moved
from an era of Cisplatin-based chemotherapy to the use
of targeted therapy, immunotherapy, and their combi-
nations. Of equal importance is the evolution of more
personalized tissue-based therapy used to guide choice.
This lecture will chronicle the 10+ year history of the
development of biopsy-based treatments for lung cancer,
evolving from the initial BATTLE trials to the Umbrella
and Master Protocols of today. The dawn of immuno-
therapy will be discussed along with efforts designed to
administer it in a more targeted way with the develop-
ment of novel biomarker and combinations.
Beyond monotherapy: Integrating
immunotherapy into current
treatment regimensKaren L. Kelly University of California, Davis,
Sacramento, CAImmunotherapy strategies targeting immune checkpoints
including PD-1, PDL-1, and CTLA-4, have garneredsubstantial enthusiasm after demonstrating clinical ac-
tivity in a broad spectrum of tumor types. In metastatic
non-small cell lung cancer (NSCLC) two randomizedphase
III trials have convincingly shown an overall survival
beneﬁt in patients receiving nivolumab in the second line
setting. The ﬁrst trial conducted in patients with squa-
mous cell histology randomized 272 patients to receive
nivolumab or docetaxel (1). The HR for OS was 0.59 (95%
CI 0.44-0.79; p<0.001). The median survival times were
9.2 months for nivoulmab and 6.0 months for docetaxel.
In the second trial performed in 582 patients with
nonsquamous cell histology nivolumab was again shown
to be superior to docetaxel with an OS HR 0.73 (95% CI
0.59-0.88; p¼0.002) and a median survival time of 12.2
months for nivoulmab and 9.4 months for docetaxel (2).
Two additional randomized trials comparing docetaxel
to pembrolizumab (anti PD-L inhibitor) or atezolizumab
(anti PDL-1 inhibitor) have completed accrual and are
likely to favor the immunotherapy arm. The efﬁcacy and
mild, non-overlapping toxicity proﬁle of immune
checkpoint inhibitors make them an ideal partner to
combine with systemic agents such as cytotoxic
chemotherapy, molecularly targeted agents and other
immune therapies in an effort to further prolong
survival for patients with advanced lung cancer.
Combinations with cytotoxic chemotherapy. The ratio-
nale for evaluating chemotherapy with immune check-
point inhibitors include: 1) tumor cell death from
conventional therapies releases neo-antigens into the
microenvironment leading to immune activation, the
recruitment of cytotoxic T cells and additional tumor cell
death 2) several cytotoxic chemotherapy agents have
been shown to promote “immunogenic cell death” and
3) systemic therapies can inﬂuence the immune micro-
environment, i.e. gemcitabine can suppress negative
immune regulators (3-5). In preclinical experiments,
chemotherapy plus PD-1, PDL-1 or CTLA-4 inhibitors
have demonstrated enhanced antitumor activity leading
to their evaluation in patients. Several phase I clinical
trials combining immune checkpoint inhibitors with a
variety of platinum based doublet have shown the
combination regimens are safe and tolerable (6-8).
Objective response rates and progression free survival
were favorable. As a result, numerous randomized
phase III trials comparing platinum doublets with or
without an immune checkpoint inhibitor are underway.
Combinations with molecularly targeted agents. The
rationale for pursuing these dual regimens is also based
on the release of neoantigens that occurs upon cell death
with effective targeted therapy (3,4). In addition
targeted therapies have been shown to remodel the
immune microenviroment. For example EGFR TKIs can
decrease PD-L1 expression and lead to tumor
regression in EGRF driven animal models (9). One
February 2016 Abstracts S9phase I clinical trial of erlotinib and nivolumab in
patients with EGFR mutated tumors has been
completed (10). The regimen was feasible and well
tolerated with promising antitumor activity. A
randomized phase III trials of an EGFR-TKI versus an
EGFR-TKI with an immune checkpoint inhibitor has
been launched. Similar preclinical evidence supports
the evaluations of ALK-TKIs plus an immune
checkpoint inhibitor (8). Phase I testing has begun.
Immunotherapy combinations. Optimizing the immune
system to attack tumors will require exploiting its diverse
components. Employing a dual immune approach with
anti- PD-1 plus an anti- CTLA-4 agents has been suc-
cessful in treating advanced melanoma. In lung cancer
phase III trials of PD-1 and CTLA-4 inhibitors have been
activated based on encouraging phase I data (12).
Meanwhile, early phase trials evaluating immune
checkpoint inhibitors with immune checkpoint agonists,
cytokines, and vaccines are ongoing to determine the
safest and most effective combinations.
Overall we are optimistic that combination regimens
that can harness the immune system together with tumor
directed therapies will lead to improved clinical beneﬁt.
Continued pursuit of optimal combinations will however
require increased insight into the complex interactions
between the tumor, the immune response and pharma-
cological interventions.
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Targeting K-Ras cancersFrank McCormick, Man-Tzu Wang UCSF Helen
Diller Family Comprehensive Cancer Center, San
Francisco, CA
Activating mutations in K-Ras occur frequently in lung
adenocarcinomas, and are mutually exclusive with other
mutations that activate the MAPK pathway, such as
EGF-R and other receptor tyrosine kinases upstream, loss
of neuroﬁbromin, loss of Spred1 and activation of B-Raf.
Neuroﬁbromin and Spred1 form a functional complex
that inactivates Ras by converting Ras.GTP to Ras.GDP.
Neuroﬁbromin has a GAP domain, and Spred1 is essential
for directing neuroﬁbromin to the plasma membrane.
Binding of neuroﬁbromin to Spred1 is regulated by
phosphorylation, so that the level of neuroﬁbromin that
can inactivate Ras is a highly regulated process. While
mutations in EGF-R, K-Ras, neuroﬁbromin, Spred1, B-Raf
and related genes are likely initiating driver mutations,
knock-down of K-Ras in cell lines often has little effect on
cell survival. This is presumed to be because feedback
loops become activated upon K-Ras ablation, keeping
cells viable. In contrast, ablation of K-Ras in pancreatic
cancer cells leads to more profound effects on survival,
for reasons that will be discussed.
Cells transformed by KRAS display a stem-like
phenotype. In contrast, cells transformed by H-Ras do
not. This difference is not related to MAPK or PI3’ kinase
activation, but is due to KRAS 4B’s’ unique ability to bind
calmodulin, and so to inhibit calmodulin-dependent ki-
nase. Low CaM kinase activity initiates a set of tran-
scriptional programs that confer stem-ness. Binding of K-
Ras to calmodulin is prevented by phosphorylation of K-
Ras on serine-181, by an unknown isoform of protein
kinase C. Treatment of mice with agents that activate
PKC disrupts KRAS binding to calmodulin and prevents
initiation and growth of tumor cells in vivo. Part of the
“stem-ness” program initiated by K-Ras involves secre-
tion of the cytokine LIF, an IL-6 family member with a
unique role in maintaining stem-ness. Neutralization of
LIF with a monoclonal antibody, or ablation of LIF
expression using siRNA or CRISPR, reduces stem-ness
